Invention Application
- Patent Title: ANTI-TIGIT ANTIBODIES AND USES THEREOF
-
Application No.: US16970351Application Date: 2019-02-28
-
Publication No.: US20210087268A1Publication Date: 2021-03-25
- Inventor: Kwang-Hoon LEE , June Hyung LEE , Na Rae LEE , Eunjeong JEONG , Young Bong PARK , Nakho CHANG , Eun-Jung LEE , Ki Hong KIM , Sunghyun CHOI , Byung Hyun CHOI , Ju Young PARK , Moo Young SONG , Jong-Seo LEE , Kyu-Tae KIM , Bong-Kook KO
- Applicant: YUHAN CORPORATION
- Applicant Address: KR Seoul
- Assignee: YUHAN CORPORATION
- Current Assignee: YUHAN CORPORATION
- Current Assignee Address: KR Seoul
- Priority: KR10-2018-0024822 20180228
- International Application: PCT/KR2019/002440 WO 20190228
- Main IPC: C07K16/28
- IPC: C07K16/28

Abstract:
Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.
The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.
The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.
Public/Granted literature
- US11505603B2 Anti-TIGIT antibodies and uses thereof Public/Granted day:2022-11-22
Information query